Grünenthal Appoints New Chief Scientific Officer and Member of Corporate Executive Board
Aachen, Germany – In a press release issued on Thursday 9 January, 2025, Grünenthal announced that Prof. Dr. Uli Brödl will be joining the company as its new Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective from 01 February 2025.
Brödl brings with him over 15 years of industry experience, having previously held the position of Corporate Senior Vice President and Head of Global Clinical Development & Operations at Boehringer Ingelheim. He was also a member of Boehringer Ingelheim’s Venture Fund Investment Committee. In his most recent role, Brödl oversaw clinical development and operations across various therapeutic areas, working closely with R&D, Commercial, and Market Access functions. He has a successful track record of bringing innovative medicines to patients, including Empagliflozin, an oral anti-diabetic medicine. Prior to his time at Boehringer Ingelheim, Brödl also led the company’s Canadian medical organization and was involved in the founding and co-chairing of the BI Canada Incubator, an innovation lab focused on developing healthcare solutions.
Brödl graduated from Ludwig-Maximilians University Munich with a degree in Medicine and is board-certified in both Internal Medicine and Endocrinology. He also holds the position of Adjunct Professor of Internal Medicine at the university.
In a statement, Brödl expressed his excitement to join Grünenthal and contribute to the company’s mission of improving the quality of life for underserved patients suffering from pain. “I am looking forward to joining the team and driving Grünenthal’s innovation pipeline,” he said.
Grünenthal’s CEO, Gabriel Baertschi, also expressed his enthusiasm for Brödl’s appointment, stating, “With Uli, we have been able to attract an excellent leader. His extensive experience in R&D and commercial functions, combined with his drive to bring innovative medicines to patients, will help us realize our vision of a world free of pain.”
Grünenthal is a global leader in pain management and related diseases, with a strong focus on science-based solutions and innovative technologies. The company operates in 27 countries across Europe, Latin America, and the U.S. and its products are available in approximately 100 countries. In 2023, Grünenthal employed around 4,400 people and achieved revenues of €1.8 billion.
For more information about Grünenthal, please visit https://www.grunenthal.com. You can also follow the company on LinkedIn (@Grunenthal Group) and Instagram (@grunenthal).
Media Contact:
Florian Dieckmann, Head of Global Corporate Affairs & Communication
Tel.: +49 241 569-2555
Florian.Dieckmann@grunenthal.com
